42926-52-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Ethoxybenzoyl chloride is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its reactivity allows for the creation of a wide range of drug molecules, contributing to the development of new medications and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Ethoxybenzoyl chloride is employed as a reagent in the synthesis of compounds used in agricultural chemicals, potentially enhancing crop protection and yield.
Used in Dye and Pigment Production:
2-Ethoxybenzoyl chloride is used as a coupling agent in the production of dyes and pigments, playing a crucial role in the coloration processes of various materials and products.
Used in Organic Synthesis:
As a reagent in organic synthesis, 2-Ethoxybenzoyl chloride is used for the preparation of esters, amides, and carboxylic acids, which are fundamental building blocks in the creation of a multitude of organic compounds for different applications.

InChI:InChI=1/C9H9ClO2/c1-2-12-8-6-4-3-5-7(8)9(10)11/h3-6H,2H2,1H3

Upstream product

• 119-36-8 methyl salicylate 
• 134-11-2 2-ethoxybenzoic acid 

Downstream Products

• 16386-47-3 2-ethoxy-benzoic acid benzo[1,3]dioxol-5-yl ester 
• 112819-13-3 2-ethoxy-benzoic acid-(1-phenyl-2-pyrrolidino-ethyl ester); hydrochloride 
• 102476-73-3 2-ethoxy-benzoic acid-(1-phenyl-2-piperidino-ethyl ester); hydrochloride 
• 69079-96-5 2-ethoxy-benzoic acid-(N-hydroxy-anilide) 
• 10263-57-7 N-(2-ethoxy-benzoyl)-glycine 
• 140836-59-5 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-2-ethoxy-benzamide 
• 123825-39-8 2-ethoxybenzoylcyanomethylenetriphenylphosphorane 
• 753385-37-4 o-Aethoxy-benzoesaeurediaethylaminoaethylester 
• 94686-72-3 2-Aethoxy-benzoat des 4-tert.-Butyl-guajacols 
• 3185-93-1 2.4.5-Trimethoxy-2'-aethoxy-benzophenon 
• 177903-42-3 (2-Ethoxy-benzoyl)-phosphonic acid dimethyl ester 
• 168626-58-2 2-ethoxy-N-[4-(5-oxo-2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-benzamide 
• 54464-18-5 4-(2-ethoxy-benzoylamino)-butyric acid 

Relevant academic research and scientific papers

Process for preparing O-ethoxybenzoic acid chloride (by machine translation)

The method comprises the following steps of (1) ethylation reaction, (2) alkali hydrolysis reaction and (3) acyl chlorination reaction, and is simple in reaction step, strong in operability, mild in reaction conditions, simple in process, easy to control, convenient to use and capable of easily controlling the byproduct HCl and CO. 2 The method is simple in process, convenient to operate, low in raw material cost, high in yield, good in quality and convenient for industrial production. (by machine translation)

Hofmann Rearrangement of Carboxamides Mediated by N-Bromoacetamide

An efficient, one-pot procedure for the Hofmann rearrangement of aromatic and aliphatic amides has been developed. Methyl and benzyl carbamates are produced with N-bromoacetamide in the presence of lithium hydroxide or lithium methoxide, in high yields. β-Phenylamino amides gave five-membered cyclic ureas stereospecifically. Side products of aryl or benzyl bromination were minimized. This procedure offers an easy access to various protected amines or diamines, which represent important synthetic precursors.

Sedinafine derivatives of the microwave-assisted method for preparing

The invention discloses a microwave-assisted synthesis method of sildenafil derivatives, which mainly comprises the following steps: by using 2-alkoxybenzoic acid and 4-amino-1-methyl-3-n-propyl-1H-pyrazolyl-5-formamide as initial raw materials, carrying out amidation, cyclization, mononitration, nitro reduction, guanidylation and the like to obtain the sildenafil derivatives. The method greatly shortens the reaction time, enhances the reaction efficiency, has the advantages of high yield and high purity, is simple to operate and easy to control, and is beneficial to industrial production of sildenafil analogs.

METHOD FOR PRODUCING OXAZOLE COMPOUND

An object of the present invention is to provide a novel method for producing an oxazole compound. The invention relates to a method for producing a compound represented by formula (1): wherein R1 is lower alkyl group or halogen substituted lower alkyl group, R2 is lower alkyl group, R5 is lower alkyl group, R11 is lower alkyl group, halogen substituted lower alkyl group or a group represented by formula: -CY2COOR12, wherein Y is a halogen atom, R12 is an alkali metal atom or lower alkyl group, Ar1 is phenyl group substituted with lower alkyl group, etc., or pyridyl group substituted with lower alkyl group, etc., X2, X3 and X9 are the same or different and are halogen atoms, X4 is a leaving group, and M is an alkali metal atom.

Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics

Small molecule choline kinase inhibitors having the following formula: are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting choline kinase enzymatic activity, and methods of treating tumors by administering an effective amount of a Formula I compound.

Synthesis of new series of pyrazolo[4,3-d]pyrimidin-7-ones and pyrido[2,3-d]pyrimidin-4-ones for their bacterial and cyclin-dependent kinases (CDKs) inhibitory activities

Two series of pyrazolo[4,3-d]pyrimidin-7-ones and pyrido[2,3-d]pyrimidin-4- ones were designed, synthesised, and evaluated for their antibacterial activities and CDKs inhibitory activities. The pyridazine derivative: 6-phenyl-5-phenylhydrazono-2,3,4,5-tetrahydropyridazine- 3,4-dione (3a) revealed activity against Staphylococcus aureus as Gram-positive bacteria while compound 2-(2- Ethoxyphenyl-5-Phenylpiperazinosulfonamido)-3H-pyrido [2,3-d]pyrimidin-4-one (13c) was showing moderate antifungal activity against Candida albicans.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Structural modifications of benzanilide derivatives, effective potassium channel openers. X.

Large-conductance calcium-activated potassium (BK) channels are involved in many fundamental cell functions. Consistently, the ability to activate BK channels by exogenous compounds is considered as a promising pharmacodynamic pattern for the potential treatment of several pathologies. In this perspective, the development of new and selective BK-openers can be considered as an actual field of research. This paper reports the synthesis and pharmacological evaluation of new benzanilides, useful for deepening the comprehension of the structure-activity relationships, emerged in previous studies on this class of BK-activators. From a structural point of view, these benzanilides belong to a general class of BK-activators, showing a common pharmacophoric model, consisting of two aryl groups linked through an appropriate "spacer" and the almost obligatory presence of a phenolic hydroxyl. In particular, a new series of benzanilides, in which the phenyl rings have been widely changed both on the acidic portion and the basic one of the amide spacer, were synthesised. Their vasorelaxing effects, induced through the activation of BK channels, were also evaluated. Although many compounds exhibited effects which could not be attributed to the activation of BK channels, two derivatives showed a clear profile of BK-activators with vasodilator activity comparable to or slightly lower than that recorded for the reference benzimidazolone NS1619. A further molecular modelling approach allowed us to obtain a molecular electrostatic potential feature which suggests a suitable interaction with the receptor site of the BK channel, from a tri-dimensional point of view. This approach seems to represent a further contribution for the development of new BK-activators, designed on the basis of the pharmacophoric model above-mentioned.

2-SUBSTITUTED PHENYL-5,7-DIALKYL-3,7-DIHYDROPYRROLE[2,3-D]PYRIMIDINE-4-ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF

The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of male and the diseases in which the function of phospholipase 5 (cGMP PDE5) is involved.